良性前列腺增生微创治疗及新技术应用研究 进展
Advances in Minimally Invasive Treatments and Novel Technologies for Benign Prostatic Hyperplasia
摘要: 目的：系统总结良性前列腺增生(BPH)微创治疗的最新进展，评估各项技术的疗效、安全性及临床应用前景。方法：检索近十年(2016~2025年) PubMed、Embase及Cochrane Library数据库中关于BPH微创治疗的临床研究、随机对照试验及相关综述，对相关文献进行筛选、归纳与综合分析。结果：以钬激光、铥激光和蓝激光为代表的激光技术不断迭代，在有效解除梗阻的同时，显著降低了出血及性功能损伤风险。以水刀机器人(Aquablation®/HYDROSTM)和水蒸气热疗消融术(RezumTM)为代表的新型能量平台，以及前列腺拉提术(UroLiftTM)等物理疗法，为患者提供了高度个性化、功能保护性更佳的治疗选择。结论：BPH微创治疗已进入精准化、个体化时代，未来的微创治疗将不再局限于手术室，而是向门诊化(Office-based)、局麻化及无植入物(Implant-free)方向演进。临床医生需根据患者对解除梗阻与保留功能(特别是射精功能)的各种权衡，提供精准的决策支持。
Abstract: Objective: To systematically review recent advancements in minimally invasive surgical therapies (MISTs) for benign prostatic hyperplasia (BPH) and to evaluate the efficacy, safety profiles, and clinical implications of these emerging technologies. Methods: A comprehensive literature search was conducted across PubMed, Embase, and the Cochrane Library databases spanning 2016 to 2025. Clinical studies, randomized controlled trials (RCTs), and relevant reviews focusing on novel MISTs for BPH were screened and synthesized. Results: Laser enucleation technologies, including Holmium (Ho:YAG), Thulium (Tm:YAG), and Blue Laser, have evolved to deliver superior hemostasis and effective obstruction relief. The novel energy platforms represented by Aquablation®/HYDROSTM and RezumTM, along with physical therapies such as UroLiftTM, offer patients highly personalized treatment options with better functional preservation. Conclusions: The landscape of BPH treatment has transitioned into an era of precision and personalization. The therapeutic paradigm is shifting from inpatient, operating-room procedures toward office-based, implant-free, and anesthesia-sparing approaches. Clinicians must employ evidence-based strategies to balance the trade-off between obstruction relief and functional preservation, tailoring interventions to meet individual patient priorities.
文章引用：罗能, 张发雄, 曾志程, 徐辉. 良性前列腺增生微创治疗及新技术应用研究 进展[J]. 临床医学进展, 2026, 16(3): 584-591. https://doi.org/10.12677/acm.2026.163825

参考文献

[1] Egan, K.B. (2016) The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urologic Clinics of North America, 43, 289-297. [Google Scholar] [CrossRef] [PubMed]
[2] Gravas, S., Cornu, J.N., Gacci, M., et al. (2024) EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology Guide-lines Office, 1-124.
[3] Checcucci, E., et al. (2025) The Current State of Artificial Intelligence for Benign Prostatic Hyperplasia: A Narrative Review. World Journal of Urology, 43, 112-118.
[4] Shah, Y.B., Im, B.H., Hochberg, A.R., Freudenburg, E.P., Jiang, J., Gao, B.M., et al. (2025) The New Gold Standard for Surgical Management of BPH: An Institutional Experience with 1000 HoLEPs. Canadian Journal of Urology, 32, 15-19. [Google Scholar] [CrossRef] [PubMed]
[5] Gkolezakis, V., Somani, B. and Tokas, T. (2023) Low-vs. High-Power Laser for Holmium Laser Enucleation of Prostate. Journal of Clinical Medicine, 12, Article No. 2084. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, L., Chen, C., Li, C., Liu, Z., Qiu, H. and Bai, H. (2025) Low-Power versus High-Power Laser for Holmium Laser Enucleation of Prostate: Systematic Review and Meta-Analysis. World Journal of Urology, 43, 228-235. [Google Scholar] [CrossRef] [PubMed]
[7] Elsaqa, M., Elgebaly, O., Sakr, M., Youssif, T.A., Rashad, H. and El Tayeb, M.M. (2022) Comparison of Outcomes of Holmium Laser versus Bipolar Enucleation of Prostates Weighing > 80 G with Bladder Outlet Obstruction. Baylor University Medical Center Proceedings, 36, 15-19. [Google Scholar] [CrossRef] [PubMed]
[8] Bach, T., Netsch, C., Haecker, A., et al. (2020) Thulium:YAG Laser Enucleation of the Prostate: Technical Aspects and Clinical Experience with More than 1000 Cases. Journal of Endourology, 34, 192-197.
[9] Taratkin, M., Checcucci, E., Androsov, A., Azilgareeva, C., Brill, B., Morozov, A., et al. (2022) Thulium Fiber Laser in BPH Surgery: Bench to Bedside—A Systematic Review on Behalf of YAU Urotechnology Working Group. Frontiers in Urology, 2, Article ID: 1017069. [Google Scholar] [CrossRef] 
[10] Gu, H., Gao, K., Wu, B., Ni, J.x., Wang, B. and Wu, G. (2025) Clinical Efficacy and Safety of Transurethral Prostate Blue Laser Vaporization versus Green Laser Vaporization in the Treatment of Benign Prostatic Hyperplasia with Different Prostate Volumes: A Retrospective Comparative Study. Medicine, 104, e43304. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, X., et al. (2025) Preservation of Sexual Function with Blue Laser Vaporization in the Treatment of Benign Prostatic Hyperplasia. Asian Journal of Andrology, 27, 45-51.
[12] Pacella, C.M., Patelli, G., Iapicca, G., et al. (2023) Transperineal Laser Ablation for Benign Prostatic Hyperplasia: A Systematic Review and Pooled Analysis of Functional Outcomes and Complications. Minerva Urology and Nephrology, 75, 143-154.
[13] PROCEPT BioRobotics (2024) PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System. Medical Device News Magazine, 12, 22-23.
[14] Gilling, P. J., Barber, N., Bidair, M., et al. (2022). Five-Year Outcomes for Aquablation Therapy Compared to TURP: Results from a Double-Blind, Randomized Trial in Men with LUTS Due to BPH. The Canadian Journal of Urology, 29, 10960-10968.
[15] Berjaoui, M.B., Nguyen, D.D., Almousa, S., Daher, K., Barber, N., Bidair, M., et al. (2024) WATER versus WATER II 5-year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cm3 and 80-150-cm3 Prostates. BJUI Compass, 5, 1023-1033.
[16] Dixon, C., Cedano, E.R., Pacik, D., Vit, V., Varga, G., Wagrell, L., et al. (2016) Two-Year Results after Convective Radiofrequency Water Vapor Thermal Therapy of Symptomatic Benign Prostatic Hyperplasia. Research and Reports in Urology, 8, 207-216. [Google Scholar] [CrossRef] [PubMed]
[17] McVary, K.T., Rogers, T. and Roehrborn, C.G. (2019) Rezūm Water Vapor Thermal Therapy for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 4-Year Results from Randomized Controlled Study. Urology, 126, 171-179. [Google Scholar] [CrossRef] [PubMed]
[18] Roehrborn, C.G., Barkin, J., Gange, S.N., et al. (2017) Five Year Results of the Prospective Randomized Controlled Prostatic Urethral L.I.F.T. Study. The Canadian Journal of Urology, 24, 8802-8813.
[19] Kaplan, S.A., Moss, J., Freedman, S., Coutinho, K., Wu, N., Efros, M., et al. (2023) The PINNACLE Study: A Double-Blind, Randomized, Sham-Controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Journal of Urology, 210, 500-509. [Google Scholar] [CrossRef] [PubMed]
[20] Smith, J., et al. (2024) Efficacy and Safety of Optilume Drug-Coated Balloon for Urethral Stricture and BPH Treatment: A Systematic Review and Meta-Analysis. Cureus, 16, e74069.
[21] Amparore, D., De Cillis, S., Schulman, C., Kadner, G., Fiori, C. and Porpiglia, F. (2023) Temporary Implantable Nitinol Device for Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms: Over 48-Month Results. Minerva Urology and Nephrology, 75, 743-751. [Google Scholar] [CrossRef] [PubMed]
[22] Manfredi, C., García-Gómez, B., Arcaniolo, D., García-Rojo, E., Crocerossa, F., Autorino, R., et al. (2022) Impact of Surgery for Benign Prostatic Hyperplasia on Sexual Function: A Systematic Review and Meta-Analysis of Erectile Function and Ejaculatory Function. European Urology Focus, 8, 1711-1732. [Google Scholar] [CrossRef] [PubMed]
[23] Altman, R., Ferreira, R., Barragan, C., Bhojani, N., Lajkosz, K., Zorn, K.C., et al. (2024) Comparing Prostatic Artery Embolization to Surgical and Minimally Invasive Procedures for the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. BMC Urology, 24, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[24] Castellani, D., et al. (2023) Learning Curve of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: A Systematic Review. World Journal of Urology, 41, 123-135.
[25] Baboudjian, M., Cornu, J., Gondran-Tellier, B., Fourmarier, M., Robert, G., Peyronnet, B., et al. (2023) Pharmacologic and Surgical Retreatment after Office-Based Treatments for Benign Prostatic Hyperplasia: A Systematic Review. European Urology Focus, 9, 727-733. [Google Scholar] [CrossRef] [PubMed]

为你推荐